Matthew A. Lunning, MD

home / authors / matthew-a-lunning-md

Articles

3 Things You Should Know About Immunotherapy in DLBCL

Matthew A. Lunning, MD;Grzegorz S. Nowakowski, MD

December 19th 2024

Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.

3 Things You Should Know About Biomarkers in DLBCL

Matthew A. Lunning, MD;Sarah C. Rutherford, MD

November 11th 2024

DLBCL is a genetically heterogeneous malignancy with multiple subtypes and recent investigations based on molecular profiles have opened the possibility for personalized therapy in this disease space.

$Relapsed or Refractory Diffuse Large B-Cell Lymphoma: “Dazed and Confused”$

Relapsed or Refractory Diffuse Large B-Cell Lymphoma: “Dazed and Confused”

Meghana Kesireddy, MBBS;Matthew A. Lunning, MD

June 16th 2022

This review article written by Meghana Kesireddy, MBBS and Matthew A. Lunning, MD, reviews management and treatment of relapsed/refractory large B-cell lymphoma.